https://esd.dof.ca.gov/Documents/bcp/2223/FY2223_ORG4140_BCP...
"This proposal will use $50 million in funding to enter into a partnership with a contract manufacturer to develop and bring to market interchangeable biosimilar insulin products in both vial and pen form."
"This proposal also includes an additional $50 million for the construction of an insulin manufacturing facility based in California. CalHHS will partner with the Governor’s Office of Business and Economic Development (GO-Biz), leveraging its expertise in business investment services such as site review, permit assistance, and other related activities. CalHHS will lean on GO-Biz’s expertise to mitigate risk and properly execute the proposed manufacturing facility, if CalRx proceeds with this component of the project."